BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24633894)

  • 1. Novel BRCA1 deleterious mutation (c.1918C>T) in familial breast and ovarian cancer syndrome who share a common ancestry.
    Gabaldó Barrios X; Sarabia Meseguer MD; Alonso Romero JL; Marín Vera M; Marín Zafra G; Sánchez Henarejos P; Sánchez Bermúdez AI; Ruiz Espejo F
    Fam Cancer; 2014 Sep; 13(3):431-5. PubMed ID: 24633894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
    Ikeda N; Miyoshi Y; Yoneda K; Shiba E; Sekihara Y; Kinoshita M; Noguchi S
    Int J Cancer; 2001 Jan; 91(1):83-8. PubMed ID: 11149425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mutational analysis of breast/ovarian cancer hereditary predisposition gene BRCA1 in Tunisian women].
    Mestiri S; Monastiri K; Ben Ahmed S; Bouaouina N; Presneau N; Bignon YJ; Khairi H; Chouchane L
    Arch Inst Pasteur Tunis; 2000; 77(1-4):11-5. PubMed ID: 14658222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 4154delA mutation carriers in the BRCA1 gene share a common ancestry.
    Ozolina S; Sinicka O; Jankevics E; Inashkina I; Lubinski J; Gorski B; Gronwald J; Nasedkina T; Fedorova O; Lyubchenko L; Tihomirova L
    Fam Cancer; 2009; 8(1):1-4. PubMed ID: 19067236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.
    Oros KK; Leblanc G; Arcand SL; Shen Z; Perret C; Mes-Masson AM; Foulkes WD; Ghadirian P; Provencher D; Tonin PN
    BMC Med Genet; 2006 Mar; 7():23. PubMed ID: 16539696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
    Johannsson O; Ostermeyer EA; Håkansson S; Friedman LS; Johansson U; Sellberg G; Brøndum-Nielsen K; Sele V; Olsson H; King MC; Borg A
    Am J Hum Genet; 1996 Mar; 58(3):441-50. PubMed ID: 8644702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.
    Shattuck-Eidens D; Oliphant A; McClure M; McBride C; Gupte J; Rubano T; Pruss D; Tavtigian SV; Teng DH; Adey N; Staebell M; Gumpper K; Lundstrom R; Hulick M; Kelly M; Holmen J; Lingenfelter B; Manley S; Fujimura F; Luce M; Ward B; Cannon-Albright L; Steele L; Offit K; Thomas A
    JAMA; 1997 Oct; 278(15):1242-50. PubMed ID: 9333265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. German family study on hereditary breast and/or ovarian cancer: germline mutation analysis of the BRCA1 gene.
    Hamann U; Brauch H; Garvin AM; Bastert G; Scott RJ
    Genes Chromosomes Cancer; 1997 Feb; 18(2):126-32. PubMed ID: 9115962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.
    Muller D; Bonaiti-Pellié C; Abecassis J; Stoppa-Lyonnet D; Fricker JP
    Fam Cancer; 2004; 3(1):15-20. PubMed ID: 15131401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in Croatia.
    Levanat S; Musani V; Cvok ML; Susac I; Sabol M; Ozretic P; Car D; Eljuga D; Eljuga L; Eljuga D
    Gene; 2012 May; 498(2):169-76. PubMed ID: 22366370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The deletion of exons 3-5 of BRCA1 is the first founder rearrangement identified in breast and/or ovarian cancer Spanish families.
    Palanca S; de Juan I; Perez-Simó G; Barragán E; Chirivella I; Martínez E; Fuster O; Bolufer P
    Fam Cancer; 2013 Mar; 12(1):119-23. PubMed ID: 23117300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
    Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
    Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests they are founder mutations for the Greek population.
    Pertesi M; Konstantopoulou I; Yannoukakos D
    Clin Genet; 2011 Oct; 80(4):375-82. PubMed ID: 20840220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry.
    Zhang B; Fackenthal JD; Niu Q; Huo D; Sveen WE; DeMarco T; Adebamowo CA; Ogundiran T; Olopade OI
    Fam Cancer; 2009; 8(1):15-22. PubMed ID: 18679828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.